We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Procalcitonin Monitoring Sepsis Study (MOSES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01523717
Recruitment Status : Completed
First Posted : February 1, 2012
Last Update Posted : March 17, 2015
Information provided by (Responsible Party):
Brahms AG

January 19, 2012
February 1, 2012
March 17, 2015
December 2011
March 2014   (Final data collection date for primary outcome measure)
28 day all cause mortality [ Time Frame: within 28 day safter inlclusion ]
participants will be followed up for 28 days
all cause in-hospital mortality [ Time Frame: duration of hospital stay up to 10 days ]
participants will be followed for the duration of hospital stay, an expected average of 10 days
Complete list of historical versions of study NCT01523717 on ClinicalTrials.gov Archive Site
all-cause in-hospital mortality [ Time Frame: mortality during hospital stay ]
count all death through out stay in the hospital
28 days mortality [ Time Frame: 28 days after enrolment ]
all cause death will be assessed within 28 days after enrolment
Not Provided
Not Provided
Procalcitonin Monitoring Sepsis Study
Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
EDTA plasma and serum samples
Probability Sample
adult patients with severe sepsis or septic shock in the emergency department, medical floor, ICU
  • Severe Sepsis
  • Septic Shock
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients (i.e. >18 years of age) diagnosed with severe sepsis or septic shock as defined in Appendix 1, who are already in the ICU or come from the ED, other wards or directly from out of hospital
  • Blood sample collection within 12 hours after diagnosis "severe sepsis or septic shock"No prior enrollment into this study
  • Written informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Brahms AG
Brahms AG
Not Provided
Principal Investigator: Nathan Shapiro, MD Beth Israel Deaconess Medical Center
Brahms AG
March 2015